Subsequently, various ongoing clinical trials utilizing CAR-T technology have been performed to target myeloma antigens such as B cell maturation antigen (BCMA), CD19, CD138 and immunoglobulin light chains 10-13. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.